$37.09
1.55% day before yesterday
Nasdaq, Jul 11, 10:04 pm CET
ISIN
US88322Q1085
Symbol
TGTX
Sector
Industry

TG Therapeutics, Inc. Stock price

$37.09
-1.24 3.22% 1M
+9.42 34.03% 6M
+6.99 23.21% YTD
+15.70 73.38% 1Y
+31.90 614.55% 3Y
+15.31 70.27% 5Y
+18.61 100.68% 10Y
-778.54 95.45% 20Y
Nasdaq, Closing price Fri, Jul 11 2025
-0.59 1.55%
ISIN
US88322Q1085
Symbol
TGTX
Sector
Industry

Key metrics

Basic
Market capitalization
$5.9b
Enterprise Value
$5.9b
Net debt
positive
Cash
$276.2m
Shares outstanding
158.2m
Valuation (TTM | estimate)
P/E
154.5 | 46.7
P/S
15.2 | 9.7
EV/Sales
15.2 | 9.7
EV/FCF
negative
P/B
24.8
Financial Health
Equity Ratio
38.5%
Return on Equity
10.5%
ROCE
12.1%
ROIC
24.8%
Debt/Equity
1.0
Financials (TTM | estimate)
Revenue
$386.4m | $605.5m
EBITDA
$59.9m | $184.8m
EBIT
$59.8m | $165.2m
Net Income
$39.2m | $125.6m
Free Cash Flow
$-61.1m
Growth (TTM | estimate)
Revenue
33.6% | 84.0%
EBITDA
23.4% | 340.1%
EBIT
23.7% | 294.1%
Net Income
-5.0% | 437.1%
Free Cash Flow
-401.3%
Margin (TTM | estimate)
Gross
87.4%
EBITDA
15.5% | 30.5%
EBIT
15.5%
Net
10.1% | 20.7%
Free Cash Flow
-15.8%
More
EPS
$0.2
FCF per Share
$-0.4
Short interest
19.5%
Employees
338
Rev per Employee
$970.0k
Show more

Is TG Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,006 stocks worldwide.

TG Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a TG Therapeutics, Inc. forecast:

12x Buy
86%
1x Hold
7%
1x Sell
7%

Analyst Opinions

14 Analysts have issued a TG Therapeutics, Inc. forecast:

Buy
86%
Hold
7%
Sell
7%

Financial data from TG Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
386 386
34% 34%
100%
- Direct Costs 49 49
160% 160%
13%
338 338
25% 25%
87%
- Selling and Administrative Expenses 170 170
32% 32%
44%
- Research and Development Expense 108 108
16% 16%
28%
60 60
23% 23%
15%
- Depreciation and Amortization 0.05 0.05
71% 71%
0%
EBIT (Operating Income) EBIT 60 60
24% 24%
15%
Net Profit 39 39
5% 5%
10%

In millions USD.

Don't miss a Thing! We will send you all news about TG Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

TG Therapeutics, Inc. Stock News

Positive
Seeking Alpha
17 days ago
TG Therapeutics, Inc.'s BRIUMVI saw Q1 2025 revenue surge 137% YoY to $119.7M, driven by strong U.S. growth. A subcutaneous version of TGTX's BRIUMVI is in phase 1 trials, with late-stage development planned for 2025, aiming to broaden patient reach and administration options. Azer-cel, an allogeneic off-the-shelf CD19 CAR-T, is in phase 1 for progressive MS, targeting a new MS market segment b...
Neutral
GlobeNewsWire
about one month ago
NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company's Chairman and Chief Executive Officer, will participate in the Goldman Sachs 46th Annual Global Healthcare Conference, being held in Miami, FL on June 9-11, 2025.
Positive
Seeking Alpha
about 2 months ago
TG Therapeutics remains on track, with Q1 revenue matching my model and potential for 110% growth in 2025 if price increases hold. Analyst estimates for 2025 revenue have risen sharply, and Q2 expectations now exceed both company guidance and my own projections. Recent price increases for Briumvi and pipeline catalysts like a subcutaneous version could drive further outperformance versus curren...
More TG Therapeutics, Inc. News

Company Profile

TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY.

Head office United States
CEO Michael Weiss
Employees 338
Founded 1993
Website www.tgtherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today